Summary
P68 is a protein kinase expressed by eukaryotic cells, which is inducible by alpha interferon, and is believed to be an important factor in the regulation of viral and cellular protein synthesis. We have previously reported on a monoclonal antibody, TJ4C4, which is able to specifically detect p68 in formalin-fixed, paraffinembedded tissue. Because of its important role in regulating cellular protein synthesis, we hypothesized that p68 expression would vary among lung neoplasms with level of differentiation and degree of biosynthetic activity. A total of 246 untreated primary pulmonary and pleural neoplasms were studied. The frequency and relative intensity of p68 expression was determined by light microscopic evaluation of ABC immunoperoxidase stained specimens. All categories of tumors studied demonstrated a spectrum of p68 expression. Expression of p68 correlated well with degree of differentiation in squamous cell carcinomas (SQCC) and acinar adenocarcinomas (AAC). Papillary adenocarcinoma (PAC) and bronchioalveolar carcinoma (BAC) expressed low levels of p68, despite their well differentiated appearance. Expression of the antigen in large cell carcinoma (LCC) was higher than that seen in either poorly differentiated AAC or SQCC. Neuroendocrine tumors generally showed low levels of p68 expression with the intermediate variant of small cell carcinoma expressing higher levels of p68 than the classic “oat cell” form (SCC). Carcinoid tumors expressed higher levels of p68 than did atypical carcinoid tumors. Mesotheliomas showed weak expression of p68, limited primarily to areas of glandular differentiation in the epithelioid form. Differential expression of p68 by lung and pleural neoplasms points to biologic differences among these tumors, serves as a good biological marker for cellular differentiation, and may provide clinically relevant information about individual tumor subtypes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aso Y, Umeda T, Niijima T (1989) Alpha interferon therapy for renal cell carcinoma: Summary of four collaborative trials. Cancer Research Committee. Progr Clin Biol Res 303:653–659
Berry MJ, Knutson GS, Lasky SR, Munemitsu SM, Samuel CE (1985) Mechanism of interferon action: Purification and substrate specificities of the double-stranded RNA-dependent protein kinase from untreated and interferon-treated mouse fibroblasts. J Biol Chem 260:11240–11247
Berry MJ, Samuel CE (1986) Mechanism of interferon action: Production and characterization of monoclonal and polyclonal antibodies to the interferon-induced phosphoprotein P1. Biochem Biophys Res Comm 133:168–175
Bolen JW, Thorning D (1980) Mesotheliomas: A lightand electron-microscopical study concerning histogenetic relationships between the epithelial and the mesenchymal variants. Am J Surg Path 4:51–64
Brook MG, McDonald JA, Karayiannis P, Caruso L, Forster G, Harris JR, Thomas HC (1989) Randomized controlled trial of interferon alpha (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 30:1116–1122
Clayton F (1986) Bronchioloalveolar carcinoma: cell types, patterns of growth, and prognostic correlates. Cancer 57:1555–1564
Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, VanThiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, and The Hepatitis Interventional Therapy Group (1989) Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomizd, controlled trial. NEJM 321:1501–1506
Galabru J, Hovanessian A (1987) Autophosphorylation of the protein kinase dependent on double-stranded RNA. J Biol Chem 262:15538–15544
Hanssen LE, Schrumpf E, Kolbenstydedt AN, Tausji J, Dolva LO (1989) Recombinant alpha-2 interferon with or without hepatic artery embolization in the treatment of midgut carcinoid tumors. A preliminary report. Acta Oncol 28:439–443
Horowitz BJ (1989) Interferon therapy for condylomatous vulvitis. Obstet Gynecol (3 Pt 1) 73:446–448
Koukoulis GK, Radosevich JA, Warren WH, Rosen ST, Gould VE (1990) Immunohistochemical analysis of pulmonary and pleural neoplasms with monoclonal antibodies B72.3 and CSLEX-1. Virchows Archiv [B] 58:427–433
Kovacs JA, Deyton L, Davey R, Falloon J, Zunich K, Lee D, Metcalf JA, Bigley JW, Sawyer LA, Zoon KC, Masur H, Fauci AS, Lane HC (1989) Combined Zidovudine and Interferonalpha therapy in patients with Kaposi Sarcoma and the acquired immunodeficiency syndrome (AIDS). Ann Int Med 111:280–287
Krown SE, Gold JWM, Niedzwiecki D, Bundow D, Flomenberg N, Gansbacher B, Brew BJ (1990) Interferon-alpha with Zidovudine: Safety, tolerance, and clinical and virologic effects in patients with Kaposi Sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Int Med 112:812–821
Laurent AG, Krust B, Galabru J, Svab J, Hovanessian AG (1985) Monoclonal antibodies to an interferon-induced Mr 68 000 protein and their use for the detection of double-stranded RNA-dependent protein kinase in human cells. Proc Natl Acad Sci USA 82:4341–4345
Matts RL, Levin DH, Petryshyn R, Thomas NS, London IM (1984) Translational control of protein synthesis in reticulocyte lysates. In: Bermek E (ed) Mechanisms of protein synthesis: structure-function relations, control mechanisms, and evolutionary aspects. Springer, Berlin Heidelberg New York Tokyo, pp 144–158
Neal MH, Kosinski R, Cohen P, Orenstein JN (1986) Atypical endocrine tumors of the lung: a histologie, ultrastructural and clinical study of 19 cases. Hum Pathol 17:1264–1268
Petryshyn R, Chen JJ, London IM (1988) Detection of activated double-stranded RNA-dependent protein kinase in 3T3-F442A cells. Proc Natl Acad Sci USA 85:1427–1431
Saldana MJ (1990) Localized diseases of the bronchi and lungs. In: Silverberg SG (ed) Principles and practice of surgical pathology, 2nd edition. Churchill, Livingstone, New York, pp 713–779
Sertoli MR, Berngngo MG, Ardizzoni A, Brunetti I, Falcone A, Vidili MG, Cusimano MP, Appino A, Doveil G, Fortini C, Rosso R (1989) Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma. Oncology 46:96–98
Taylor JL, Samuel CE, Grossberg SE (1988) Antiviral and antidifferentiative activities of Interferon Beta and Gamma in relation to their induction of double-stranded RNA-dependent protein kinase activity in 3T3-L1 cells. J Biol Chem 263:1336–1341
World Health Organization (1982) The World Health Organization histological typing of lung tumors, 2nd edition. Am J Clin Pathol 77:123–136
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haines, G.K., Ghadge, G., Thimmappaya, B. et al. Expression of the protein kinase p-68 recognized by the monoclonal antibody TJ4C4 in human lung neoplasms. Virchows Archiv B Cell Pathol 62, 151–158 (1992). https://doi.org/10.1007/BF02899677
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02899677